Fluzoparib and apatinib for maintenance in advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether taking fluzoparib (a PARP inhibitor) plus apatinib (a targeted therapy) after initial chemotherapy can help keep advanced ovarian, fallopian tube, or primary peritoneal cancer from coming back. It is for people who have finished their first treatment and are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV high-grade serious ovarian cancer, fallopian tube cancer, primary peritoneal cancer, or endometrioid ovarian cancer.
- You have not taken a PARP inhibitor before as maintenance therapy.
- Your last chemotherapy included bevacizumab, paclitaxel, and carboplatin.
- Your CA-125 blood marker shows a good drop during treatment (KELIM score of 1 or higher).
- You are in good physical condition (ECOG score 0 or 1) and your major organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs (fluzoparib and apatinib) as maintenance therapy after chemotherapy for women with relapsed ovarian cancer. It might help keep the cancer from coming back for those who have already responded well to platinum-based chemo.
This Phase 2 trial tests whether adding two medicines (fluzoparib plus apatinib) works better than fluzoparib alone to keep recurrent ovarian, fallopian tube, or primary peritoneal cancer from growing. It targets people whose cancer responded to recent platinum chemotherapy and who previously took a PARP inhibitor as maintenance therapy.
This trial tests a combination of two oral medications—fluzoparib (a PARP inhibitor) and famitinib (a TKI)—as maintenance therapy to keep advanced ovarian cancer from coming back after successful first-line chemotherapy. It is for women whose cancer responded well to initial platinum-based treatment.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This study tests two oral medications (Fluzopril and Apatinib) as a maintenance treatment to keep ovarian cancer from growing after initial chemotherapy. It is for women whose cancer returned within 6 months of platinum-based chemo, and who are currently stable after their last chemo cycle.
This trial tests whether a maintenance treatment with fluzoparib (a PARP inhibitor) plus bevacizumab can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation and whose cancer responded to initial chemotherapy.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.